NCCN, AstraZeneca Projects Target Advanced Ovarian Cancer Patients

NCCN, AstraZeneca Projects Target Advanced Ovarian Cancer Patients
Four projects chosen by the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program will explore ways to use technology to improve care for advanced ovarian cancer patients. Funded by AstraZeneca, the two-year projects will begin the third quarter of this year. They are expected to provide measurable outcome steps, and be reproducible, scalable and swiftly implemented. Advanced ovarian cancer means the malignancy has spread outside the ovaries. “Advanced and recurrent ovarian cancer is currently the deadliest gynecologic cancer,” Wui-Jin Koh, MD, chief medical officer, NCCN, said in a press release. “It requires a multidisciplinary approach for management, which can provide challenges for optimal coordination. These projects will explore opportunities to leverage technology in order to improve patient outcomes and quality of life through supportive services, shared decision making, and innovative methods of care delivery,” he said. The projects also will emphasize strategies intended to help close disparity gaps in ovarian cancer healthcare delivery, he said. Cary Gross, MD, of Yale School of Medicine’s  Cancer Outcomes, Public Policy, and Effectiveness Research Center, will lead a project titled “CommunityRx-
Subscribe or to access all post and page content.